Literature DB >> 9264072

The effect of cumulative dosing on the analgesic potency of morphine in mice.

A Duttaroy1, R Kirtman, F Farrell, M Phillips, J Philippe, T Monderson, B C Yoburn.   

Abstract

Opioid analgesic potency can be evaluated using cumulative dosing, in which subjects are repeatedly administered a drug and tested after each dose until a criterion effect is reached. Although many laboratories use cumulative dosing, the effects of varying the starting dose and the magnitude of the increment dose on morphine analgesia (tail flick) in mice have not been evaluated. In experiment 1. mice were injected with the same starting dose [0.5 mg/kg subcutaneously (SC)] and 30 min later were tested for analgesia. Mice that were not analgesic were administered an increment dose (0.5, 1.0, 2.0, 2.5, or 3.0 mg/kg) and retested. The process was continued until all mice were analgesic. There was a significant effect of increment dose on morphine potency, with the relative potency increasing as the increment dose was increased. In experiment 2, different starting doses (0.5, 1.0, 2.0, or 3.0 mg/kg) were used with a constant increment dose of 1.0 mg/kg. There was a significant effect of starting dose on the potency of morphine, with the relative potency increasing as the starting dose increased. To determine if increment and starting dose affect tolerance estimates, mice were implanted SC with a 25- or 75-mg morphine or placebo pellet for 7 days and then tested using cumulative dose-response. Changes in the increment dose significantly affected the degree of tolerance for mice implanted with a 25-mg morphine pellet but not for mice implanted with a 75-mg morphine pellet. Changes in the starting dose did not significantly alter estimates of tolerance. Overall, these data indicate that the starting dose and increment dose can impact on morphine's potency determined by cumulative dosing protocols. Furthermore, estimates of tolerance can be affected by dosing parameters in the cumulative dosing protocol. These results suggest that cumulative dosing procedures should be standardized across experiments.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9264072     DOI: 10.1016/s0091-3057(96)00463-7

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  11 in total

1.  Persistent exercise attenuates nicotine- but not clonidine-induced antinociception in female rats.

Authors:  Wendy Foulds Mathes; Robin B Kanarek
Journal:  Pharmacol Biochem Behav       Date:  2007-01-02       Impact factor: 3.533

2.  Morphine analgesic tolerance in 129P3/J and 129S6/SvEv mice.

Authors:  Camron D Bryant; Kristofer W Roberts; Janet S Byun; Michael S Fanselow; Christopher J Evans
Journal:  Pharmacol Biochem Behav       Date:  2006-12-28       Impact factor: 3.533

3.  OPRM1 Methylation Contributes to Opioid Tolerance in Cancer Patients.

Authors:  Chi T Viet; Dongmin Dang; Bradley E Aouizerat; Christine Miaskowski; Yi Ye; Dan T Viet; Kentaro Ono; Brian L Schmidt
Journal:  J Pain       Date:  2017-04-27       Impact factor: 5.820

4.  Hydromorphone efficacy and treatment protocol impact on tolerance and mu-opioid receptor regulation.

Authors:  Priyank Kumar; Soujanya Sunkaraneni; Sunil Sirohi; Shveta V Dighe; Ellen A Walker; Byron C Yoburn
Journal:  Eur J Pharmacol       Date:  2008-08-30       Impact factor: 4.432

5.  Inhibition of the development of morphine tolerance by a potent dual mu-delta-opioid antagonist, H-Dmt-Tic-Lys-NH-CH2-Ph.

Authors:  Yunden Jinsmaa; Ewa D Marczak; Gianfranco Balboni; Severo Salvadori; Lawrence H Lazarus
Journal:  Pharmacol Biochem Behav       Date:  2008-10       Impact factor: 3.533

6.  Contribution of dopamine receptors to periaqueductal gray-mediated antinociception.

Authors:  Paul J Meyer; Michael M Morgan; Laura B Kozell; Susan L Ingram
Journal:  Psychopharmacology (Berl)       Date:  2009-02-19       Impact factor: 4.530

7.  Dosing protocol and analgesic efficacy determine opioid tolerance in the mouse.

Authors:  Priyanka A Madia; Shveta V Dighe; Sunil Sirohi; Ellen A Walker; Byron C Yoburn
Journal:  Psychopharmacology (Berl)       Date:  2009-10-09       Impact factor: 4.530

8.  Analgesic tolerance to microinjection of the micro-opioid agonist DAMGO into the ventrolateral periaqueductal gray.

Authors:  Paul J Meyer; Erin N Fossum; Susan L Ingram; Michael M Morgan
Journal:  Neuropharmacology       Date:  2007-03-12       Impact factor: 5.250

9.  The analgesic efficacy of fentanyl: relationship to tolerance and mu-opioid receptor regulation.

Authors:  Sunil Sirohi; Shveta V Dighe; Ellen A Walker; Byron C Yoburn
Journal:  Pharmacol Biochem Behav       Date:  2008-06-30       Impact factor: 3.533

10.  A large animal neuropathic pain model in sheep: a strategy for improving the predictability of preclinical models for therapeutic development.

Authors:  Denise Wilkes; Guangwen Li; Carmina F Angeles; Joel T Patterson; Li-Yen Mae Huang
Journal:  J Pain Res       Date:  2012-10-25       Impact factor: 3.133

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.